Tags

Type your tag names separated by a space and hit enter

Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Breast Cancer. 2012 Oct; 19(4):309-14.BC

Abstract

BACKGROUND

Topoisomerase II alpha (Topo IIa) is involved in DNA replication and is a molecular target for anthracycline-based chemotherapy. The Ki-67 labeling index (LI) is an evaluation of tumor cell proliferation. The objective of this study was to evaluate relationships among Topo IIa expression, the Ki-67 LI, and prognostic factors in estrogen receptor (ER)-positive, human epidermal growth factor type-2 (HER2)-negative breast cancer.

MATERIALS AND METHODS

Seventy-one patients were diagnosed with ER-positive, HER2-negative breast cancer between July 2003 and December 2004. Formalin-fixed, paraffin-embedded tumor specimens were stained for Topo IIa expression and Ki-67 LI. We investigated the correlation of the level of Topo IIa expression and the Ki-67 LI with clinical factors such as age, tumor size, progesterone receptor status, nodal status, nuclear grade, and lymphovascular invasion (LVI).

RESULTS

Statistically significant differences were observed between Topo IIa overexpression, nuclear grade (p = 0.036), and LVI (p = 0.029). Topo IIa overexpression was statistically correlated with the Ki-67 LI (p < 0.0001). A statistically significant difference was observed between the Ki-67 LI and nuclear grade (p = 0.01). Survival analysis revealed the significant prognostic value of Ki-67 LI in patients with ER-positive, HER2-negative breast cancer (p = 0.003).

CONCLUSIONS

Ki-67 LI is a strong prognostic factor in ER-positive HER2-negative breast cancer. Topo IIa overexpression was significantly correlated with the Ki-67 LI, nuclear grade, and LVI. These findings suggest use of Topo IIa expression as a proliferation marker and a prognostic factor in ER-positive, HER2-negative breast cancer.

Authors+Show Affiliations

Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan. tokiniwa@med.gunma-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21725655

Citation

Tokiniwa, Hideaki, et al. "Topoisomerase II Alpha Expression and the Ki-67 Labeling Index Correlate With Prognostic Factors in Estrogen Receptor-positive and Human Epidermal Growth Factor Type-2-negative Breast Cancer." Breast Cancer (Tokyo, Japan), vol. 19, no. 4, 2012, pp. 309-14.
Tokiniwa H, Horiguchi J, Takata D, et al. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. Breast Cancer. 2012;19(4):309-14.
Tokiniwa, H., Horiguchi, J., Takata, D., Kikuchi, M., Rokutanda, N., Nagaoka, R., Sato, A., Odawara, H., Tozuka, K., Oyama, T., & Takeyoshi, I. (2012). Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. Breast Cancer (Tokyo, Japan), 19(4), 309-14. https://doi.org/10.1007/s12282-011-0291-4
Tokiniwa H, et al. Topoisomerase II Alpha Expression and the Ki-67 Labeling Index Correlate With Prognostic Factors in Estrogen Receptor-positive and Human Epidermal Growth Factor Type-2-negative Breast Cancer. Breast Cancer. 2012;19(4):309-14. PubMed PMID: 21725655.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. AU - Tokiniwa,Hideaki, AU - Horiguchi,Jun, AU - Takata,Daisuke, AU - Kikuchi,Mami, AU - Rokutanda,Nana, AU - Nagaoka,Rin, AU - Sato,Ayako, AU - Odawara,Hiroki, AU - Tozuka,Katsunori, AU - Oyama,Tetsunari, AU - Takeyoshi,Izumi, Y1 - 2011/07/02/ PY - 2011/03/22/received PY - 2011/06/14/accepted PY - 2011/7/5/entrez PY - 2011/7/5/pubmed PY - 2013/4/23/medline SP - 309 EP - 14 JF - Breast cancer (Tokyo, Japan) JO - Breast Cancer VL - 19 IS - 4 N2 - BACKGROUND: Topoisomerase II alpha (Topo IIa) is involved in DNA replication and is a molecular target for anthracycline-based chemotherapy. The Ki-67 labeling index (LI) is an evaluation of tumor cell proliferation. The objective of this study was to evaluate relationships among Topo IIa expression, the Ki-67 LI, and prognostic factors in estrogen receptor (ER)-positive, human epidermal growth factor type-2 (HER2)-negative breast cancer. MATERIALS AND METHODS: Seventy-one patients were diagnosed with ER-positive, HER2-negative breast cancer between July 2003 and December 2004. Formalin-fixed, paraffin-embedded tumor specimens were stained for Topo IIa expression and Ki-67 LI. We investigated the correlation of the level of Topo IIa expression and the Ki-67 LI with clinical factors such as age, tumor size, progesterone receptor status, nodal status, nuclear grade, and lymphovascular invasion (LVI). RESULTS: Statistically significant differences were observed between Topo IIa overexpression, nuclear grade (p = 0.036), and LVI (p = 0.029). Topo IIa overexpression was statistically correlated with the Ki-67 LI (p < 0.0001). A statistically significant difference was observed between the Ki-67 LI and nuclear grade (p = 0.01). Survival analysis revealed the significant prognostic value of Ki-67 LI in patients with ER-positive, HER2-negative breast cancer (p = 0.003). CONCLUSIONS: Ki-67 LI is a strong prognostic factor in ER-positive HER2-negative breast cancer. Topo IIa overexpression was significantly correlated with the Ki-67 LI, nuclear grade, and LVI. These findings suggest use of Topo IIa expression as a proliferation marker and a prognostic factor in ER-positive, HER2-negative breast cancer. SN - 1880-4233 UR - https://www.unboundmedicine.com/medline/citation/21725655/Topoisomerase_II_alpha_expression_and_the_Ki_67_labeling_index_correlate_with_prognostic_factors_in_estrogen_receptor_positive_and_human_epidermal_growth_factor_type_2_negative_breast_cancer_ L2 - https://dx.doi.org/10.1007/s12282-011-0291-4 DB - PRIME DP - Unbound Medicine ER -